Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Am J Cardiol. 2021 Feb 2;146:15–21. doi: 10.1016/j.amjcard.2021.01.017

Figure 1: sACE2 and cardiac biomarkers, structure, and function: potential implication for CVD.

Figure 1:

Pathological activation of RAAS as evidenced by elevated sACE2 levels was associated with elevated cardiac biomarkers and echocardiographic measures of cardiac structural abnormalities and diastolic dysfunction, and independently predicted cardiovascular events including heart failure hospitalizations.